Bio-Rad Corp (BIO): Long-Term Debt to Capital Ratio

The confirmed price history on the Bio-Rad Laboratories (BIO) chart demonstrates metrics at the level of 0.14. The business focuses on leadership in diagnostics, deploying PCR equipment and generating revenue from exclusive consumables. Efficiency is maintained by outsourcing logistics and component synthesis to external partners. Stable growth is driven by the implementation of digital analysis methods and the updating of the test line for biopharmaceuticals.

Bio-Rad Laboratories (BIO) maintains a stable cash flow through seamless logistics and an extensive warehouse network, enabling the company to optimize its long-term liabilities. By analyzing the long-term debt-to-equity ratio, an investor assesses the proportion of loans with maturities exceeding one year relative to equity, which helps distinguish strategic business development from a critical dependence on borrowed funds and allows for the timely diagnosis of the issuer's solvency.